SLC29A1 and epilepsy: As described above, several BBB-permeable ENT1 inhibitors have recently been developed as potential drug candidates for the treatment of multiple neurodegenerative diseases, including AD, HD, ALS, and epilepsy [46, 111, 127, 141, 144].